Associated Press logo
USA TODAY logo
CNBC logo
4 articles
·7M

FDA Declares End to Ozempic and Wegovy Shortages After Two Years

The FDA announces the resolution of the prolonged shortages of Ozempic and Wegovy, allowing Novo Nordisk to meet U.S. demand for these treatments.

Subscribe to unlock this story

We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!

Get Started

Have an account? Sign in

Overview

A summary of the key points of this story verified across multiple sources.

The FDA has declared the shortages of popular diabetes and weight loss drugs Ozempic and Wegovy resolved, enabling Novo Nordisk to meet current and future demand. Despite this, intermittent supply disruptions may occur during the distribution process. The resolution comes after Novo Nordisk invested $6.5 billion in production capacity in the U.S. Since 2022, compounded versions of these medications had provided alternative access, raising concerns as their production may become limited with the official end of the shortage. The ongoing market dynamics may impact competitors in the burgeoning weight loss drug industry.

Written by AI using shared reports from
4 articles
.

Report issue

Pano Newsletter

Read both sides in 5 minutes each day

Analysis

Compare how each side frames the story — including which facts they emphasize or leave out.

Analysis unavailable for this viewpoint.

Articles (4)

Compare how different news outlets are covering this story.

FAQ

Dig deeper on this story with frequently asked questions.

The resolution of the shortages was primarily due to Novo Nordisk's substantial efforts to increase manufacturing capacity, including a $6.5 billion investment in U.S. production facilities. This allowed them to meet or exceed current and projected U.S. demand for these medications.

The end of the shortages could impact companies like Hims & Hers, which have been producing compounded versions under FDA rules allowing mass production when the originals are hard to obtain. The FDA has stated it will not take action against these compounders for a limited time to avoid disrupting patient treatment.

Although the shortages are resolved, there may still be intermittent and limited localized supply disruptions as products move through the supply chain.

History

See how this story has evolved over time.

  • This story does not have any previous versions.